Isofol Announces the Appointment of Robert Marchesani as an Advisor to its Board of Directors
GOTHENBURG, Sweden, November 16, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the appointment of […]
Corporate Information
Isofol Announces Initiation of a Pivotal Phase 3 Clinical Trial of arfolitixorin for the Treatment of Metastatic Colorectal Cancer
GOTHENBURG, Sweden, November 15, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL) today announced initiation of the
New Chairman and extended board at Isofol Medical AB (publ)
Isofol Medical AB (publ), developing arfolitixorin as treatment for advanced colorectal cancer is calling an Extraordinary General Meeting on Wednesday
Patent approved in the United States for Isofol’s drug candidate arfolitixorin
The patent now approved in the United States expires in 2037 and covers both the Active Pharmaceutical Ingredient (arfolitixorin hemisulfate),
Redeye and Isofol are inviting to the live broadcast of pre-ASCO on May 28th
In connection to this year’s major cancer congress ASCO (American Society of Clinical Oncology (https://www.asco.org/)) in Chicago in June, Redeye brings
Isofol announces that an abstract with new research resultshas been published for this year’s ASCO congress in Chicago
Isofol Medical AB (publ) announces that a scientific abstract has been published for this year’s annual Congress of the American
Isofol reports FDAs feedback from the ongoing special protocol assessment (SPA) process
In March 2018, Isofol Medical AB (publ) submitted a Special Protocol Assessment (SPA) to the United States Food and Drug
Isofol announces that an abstract describing a genetic prediction of treatment response in CRC treatment to be unveiled at ASCO 2018
Isofol Medical AB (publ) announces that an abstract describing correlation between expression levels of folate-related genes in tumours with progression-free
Isofol Medical has selected arfolitixorin-dose for the phase III pivotal study ISO-CC-007
The selected dose for the drug candidate arfolitixorin of 120 mg/m2, (approximately 200 mg for an adult male) is based
Isofol Medical adopts the World Health Organization recommended name (INN) arfolitixorin for Modufolin®
Isofol Medical AB (publ) today announce that the company will in the future be adopting the generic name arfolitixorin for